Bristol Myers Squibb stock jumped after the pharma company won approval for its new schizophrenia drug late Thursday. “This ...
Bristol Myers surges after the FDA approves an oral medication for schizophrenia in adults, fiscal fourth-quarter revenue at ...
Stock futures were modestly higher ahead of the release of the Federal Reserve's preferred measures of inflation, as major ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Bristol-Myers Squibb (NYSE:BMY) shares rallied 4.45% in premarket trading Friday following the announcement that the U.S. Food and Drug Administration (FDA) approved the company's new schizophrenia ...
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
The US Food and Drug Administration has approved the new drug Cobenfy, which is owned by pharmaceutical firm Bristol Myers ...
The treatment offers hope to thousands of patients who do not respond to existing medications, and has shown promise in treating other neurological disorders.
US stock futures were broadly muted on Friday as investors awaited the release of a raft of economic data, including new consumer spending figures and the Federal Reserve's preferred gauge of ...
The US Food and Drug Administration has granted approval to Bristol-Myers Squibb’s drug Cobenfy® (xanomeline and trospium ...
KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.
Data through the week points to a still-resilient economy overall, leaving traders uncertain about the Fed’s next move.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback